Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Short-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Short-Term Debt repayments (2017 - 2025)

Historic Short-Term Debt repayments for Myriad Genetics (MYGN) over the last 7 years, with Q3 2025 value amounting to $60.0 million.

  • Myriad Genetics' Short-Term Debt repayments rose 20000.0% to $60.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.0 million, marking a year-over-year decrease of 2857.14%. This contributed to the annual value of $119.5 million for FY2024, which is 19875.0% up from last year.
  • Latest data reveals that Myriad Genetics reported Short-Term Debt repayments of $60.0 million as of Q3 2025, which was up 20000.0% from $20.5 million recorded in Q1 2025.
  • Myriad Genetics' Short-Term Debt repayments' 5-year high stood at $106.4 million during Q3 2021, with a 5-year trough of $19.5 million in Q4 2024.
  • Moreover, its 4-year median value for Short-Term Debt repayments was $45.0 million (2021), whereas its average is $46.6 million.
  • Examining YoY changes over the last 5 years, Myriad Genetics' Short-Term Debt repayments showed a top increase of 20000.0% in 2025 and a maximum decrease of 6583.33% in 2025.
  • Quarter analysis of 4 years shows Myriad Genetics' Short-Term Debt repayments stood at $106.4 million in 2021, then tumbled by 62.41% to $40.0 million in 2023, then tumbled by 51.25% to $19.5 million in 2024, then surged by 207.69% to $60.0 million in 2025.
  • Its Short-Term Debt repayments was $60.0 million in Q3 2025, compared to $20.5 million in Q1 2025 and $19.5 million in Q4 2024.